title: Genetic/familial high-risk assessment: breast and ovarian, version 1.2014.
abstract: During the past few years, several genetic aberrations that may contribute to increased risks for development of breast and/or ovarian cancers have been identified. The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast and Ovarian focus specifically on the assessment of genetic mutations in BRCA1/BRCA2, TP53, and PTEN, and recommend approaches to genetic testing/counseling and management strategies in individuals with these mutations. This portion of the NCCN Guidelines includes recommendations regarding diagnostic criteria and management of patients with Cowden Syndrome/PTEN hamartoma tumor syndrome.
authors.forename: Mary B
authors.initials: MB
authors.lastname: Daly
authors.forename: Robert
authors.initials: R
authors.lastname: Pilarski
authors.forename: Jennifer E
authors.initials: JE
authors.lastname: Axilbund
authors.forename: Saundra S
authors.initials: SS
authors.lastname: Buys
authors.forename: Beth
authors.initials: B
authors.lastname: Crawford
authors.forename: Susan
authors.initials: S
authors.lastname: Friedman
authors.forename: Judy E
authors.initials: JE
authors.lastname: Garber
authors.forename: Carolyn
authors.initials: C
authors.lastname: Horton
authors.forename: Virginia
authors.initials: V
authors.lastname: Kaklamani
authors.forename: Catherine
authors.initials: C
authors.lastname: Klein
authors.forename: Wendy
authors.initials: W
authors.lastname: Kohlmann
authors.forename: Allison
authors.initials: A
authors.lastname: Kurian
authors.forename: Jennifer
authors.initials: J
authors.lastname: Litton
authors.forename: Lisa
authors.initials: L
authors.lastname: Madlensky
authors.forename: P Kelly
authors.initials: PK
authors.lastname: Marcom
authors.forename: Sofia D
authors.initials: SD
authors.lastname: Merajver
authors.forename: Kenneth
authors.initials: K
authors.lastname: Offit
authors.forename: Tuya
authors.initials: T
authors.lastname: Pal
authors.forename: Boris
authors.initials: B
authors.lastname: Pasche
authors.forename: Gwen
authors.initials: G
authors.lastname: Reiser
authors.forename: Kristen Mahoney
authors.initials: KM
authors.lastname: Shannon
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Swisher
authors.forename: Nicoleta C
authors.initials: NC
authors.lastname: Voian
authors.forename: Jeffrey N
authors.initials: JN
authors.lastname: Weitzel
authors.forename: Alison
authors.initials: A
authors.lastname: Whelan
authors.forename: Georgia L
authors.initials: GL
authors.lastname: Wiesner
authors.forename: Mary A
authors.initials: MA
authors.lastname: Dwyer
authors.forename: Rashmi
authors.initials: R
authors.lastname: Kumar
mesh_terms: D019468:Disease Management; D005260:Female; D005817:Genetic Counseling; D005820:Genetic Testing; D018095:Germ-Line Mutation; D006223:Hamartoma Syndrome, Multiple / Q000175:diagnosis* / Q000235:genetics*; D006801:Humans; D008297:Male